RNTX — Rein Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $28.43m
- $67.72m
Annual income statement for Rein Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 20.5 | 26.3 | 27.6 | 16.3 | 65.1 |
| Operating Profit | -20.5 | -26.3 | -27.6 | -16.3 | -65.1 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21.2 | -26.2 | -27.3 | -15.7 | -64.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -21.2 | -26.2 | -27.3 | -15.7 | -62.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -21.2 | -26.2 | -27.3 | -15.7 | -62.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -21.2 | -26.2 | -27.3 | -15.7 | -62.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -11.7 | -5.98 | -6.02 | -3.23 | -2.16 |